Share Name Share Symbol Market Type Share ISIN Share Description
Inspiration Healthcare Group Plc LSE:IHC London Ordinary Share GB00BXDZL105 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -0.51% 97.00 97.00 98.00 97.50 94.00 96.50 25,248 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 17.8 1.1 2.2 44.3 66

Inspiration Healthcare Share Discussion Threads

Showing 776 to 798 of 800 messages
Chat Pages: 32  31  30  29  28  27  26  25  24  23  22  21  Older
Anyone got any targets in mind for this one?
Pratt2 how many times has Robbie Burns aka the Naked Trader stated not to list his high risk share on these bulletin boards people have registered and paid him for these high risk tips.
Hi Pratt, where did you read this about NT buying? Not in diary? either way awesome rise and I bought in the mid 80's
thanks Pratt, I did check his website but it doesnt say he did and that was updated yesterday?
Bought by the naked trader yest. Target price 200
Hi - I found this article that was issued a week ago... HTTPS:// Inspiration Healthcare’s neonatal care drives hefty upgrades Operating profit estimates upgraded 18 per cent. SLE acquisition delivers increasing sales. Crawley-based Inspiration Healthcare (IHC:90p), a fully integrated medical technology company with a strong focus on the high growth neonatal intensive care market, is reaping the benefits of last summer’s £18m complementary acquisition of SLE, a designer and manufacturer of four types of ventilators for neonatal intensive care. SLE always looked like a good fit. That’s because Inspiration’s range of neonatal respiratory products support and assist the care of preterm infants by providing resuscitation, stabilisation and respiratory support. SLE’s sales have increased steadily since the deal completed in July, partly due to one-off Covid-19 orders but also reflects other factors such as cross-selling opportunities across the enlarged group (neonatal respiratory disposables and breathing circuits, for example). Inspiration’s directors note that the operational savings identified at the time of the acquisition are being achieved. The addition of SLE’s 30,000 sq. ft. facility in Croydon for the assembly of technically advanced capital equipment means that Inspiration now has 50,000 sq. ft. of manufacturing capacity. Inspiration is now less reliant on third party products, too. Moreover, with Inspiration’s annual revenue set to more than double to at least £36.5m (3 per cent ahead of forecasts) on a gross margin of around 43.6 per cent, then a higher proportion of incremental margin earned drops through to profit given Inspiration’s relatively fixed cost base. This explains why house broker Cenkos Securities has raised its operating profit estimate by 18 per cent to £2.86m, an 88 per cent year-on-year increase. On this basis, Cenkos expects adjusted EPS of 5.9p, up from 3.8p in the 2019/20 financial year, and closing net cash of £5.4m (8p a share). The SLE acquisition was one reason why I suggested buying the shares, at 75p (Alpha Research: ‘Profit from a medical technology winner’, 27 October 2020), noting that the enlarged business is well placed to benefit from organic growth trends in overseas markets while reaping synergy benefits across a wider customer base. Those dynamics are still at play. So, with the shares priced on a modest cash-adjusted forward PE ratio of 13.5, I maintain my 105p target price. Buy.
Does anyone know if this has been tipped? thanks Even at this level there is no stock to buy!
Great to see IHC smashing through £1. Cant see any particular reason why. Have I missed anything?
Ah - no wonder the price has risen! Must admit to being surprised at IHC reaching these levels. Well done to holders here. I sold too early but from memory I suspect the proceeds went into other stocks which have also risen since. So swings and roundabouts!
Recommended by Simon T in IC. Positive piece. Target 105p
Picked some of these up recently, really like the breakout after such a long time and they seem to be doing the business in a strong sector right now.
Results ahead of expectations and broker has increased FCs for FY22 too: hTTps://
Good to see GeneDrive's trial being successful for the Genedrive® MT-RNR1 ID Kit "Genedrive is now working with the study team to publish the data, due in early 2021, and with Inspiration Healthcare plc to plan the roll-out for commercial use. Full launch of the product is expected from June 2021, following the inclusion of feedback from the trial sites in the product configuration."
The NHS ventilators have been delivered and paid for. There should be nothing in the price for them now, they are history. Ventilators are used for other things other than COVID though so they will be used/sold on. If you believe that the vaccine announcement yesterday is going to stop Covid in it's tracks, then you have been blinkered by the hysteria, they are a long way off getting it out to the general population and with plenty of Worldwide competition for the vaccines the UK will need to keep testing/isolating/Social distancing, etc for many, many months yet. But there should be nothing Covid in the price of IHC, because it stepped up and did it's bit and got paid for it, there were never going to be further Covid orders. They will get lots of orders from around the World for their neo-natal equipment (including specialist ventilators)as well as their equipment for use in operating theatres and ICU depts. So all looking very good on the business front.
so, how much of the price do we think is due to the ventilators that will not be needed if the vaccine works?
The spread here is ridiculous and on the trades showing so far, seems just an attempt to shake out some stop losses. Perhaps they don't realise the Ventilators for the NHS was a one off and their other ventilators and equipment are for the neo-natal market and that will always be needed.
I've taken advantage of the Simon Thompson-induced rise to take decent profits and sell out yesterday and today. This is partly because I needed to top up funds after investing elsewhere (CLX if anyone's interested - see my thread). But also because I'm a little unsure about IHC. The P/E to Jan' 22 is now around 17, which isn't cheap. The big SLE acquisition is apparently heavily weighted towards IHC's H1, so growth in this current H2 to Jan'21 may look somewhat light. Finally, the pandemic has caused a fall in already declining global birth rates. GLA - IHC looks a decent company, I'm just not sure that the high P/E is justified by the forward earnings and other factors. Though of course further large acquisitions could change all that!
"kept the faith"- not much take up for the heated pitches that I invested for!
Fabulous rise today - tipped by Midas (Daily Mail) a couple of week ago; then Moneyweek tipped, then Investors Chronicle today. Simon Thompson Target is for 105p - for early 2021 on FY results. I've top sliced a few today, as my portfolio was top heavy with IHC. Still keeping a very significant number though with target 100p+ Well done all holders who kept the faith with IHC despite the MMs walking the share price down at every opportunity! It makes a nice change to see this share rising strongly today. Rich
Conclusion As investors start to recognise that the contribution from the SLE acquisition will more than replace the one-off NHS ventilator sales which have boosted current year profits, it’s reasonable to expect the shares to start to re-rate towards the upper end of their historic EV/Ebitda valuation range (8 to 14 times multiple since 2016), up from the current 9 times multiple based on 2021/22 forecasts. Based on 13 times multiple then Inspiration’s enterprise valuation rises to £65m implying a market capitalisation of £71m (105p a share) after factoring in the £5.7m forecast cash pile at 31 January 2022. That’s 40 per cent above the current share price, highlighting the scope for a major re-rating. So, having taken the risk assessment below into account, and the positive trading outlook for the company, the risk-to-reward here is favourable. The shares are well worth buying ahead of the full-year trading update early next year. Buy.
Cheers - wondered what was going on! Interesting that it started rising yesterday....
Just got a copy of the IC Alpha report. Its a comprehensive 16 page report by Simon Thomson on IHC. The conclusion is that there is major potential upside with an implied valuation of around 105p per share.
pmeldrum: thanks. Babbler: ST= Simon Thompson, influential tipster in Investors Chron.
Chat Pages: 32  31  30  29  28  27  26  25  24  23  22  21  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210228 01:20:15